Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693960 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
A Early Phase 1 study of Interaction, sponsored by Washington State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06693960: Recruiting Early Phase 1 study of Interaction, sponsored by Washington State University.
NCT06693960 is a Early Phase 1 study of Interaction that is actively recruiting participants, run by Washington State University. The registered enrollment target is 16 participants, below the 23-participant average among 3 other Interaction trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06693960, a Early Phase 1 study of Interaction, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.
Primary Outcome
Ratio of the area under the plasma concentration vs. time curve of midazolam in the presence to absence of oregano.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Oregano
- DRUG Drug cocktail
Study Locations (1)
Washington
- Washington State University College of Pharmacy and Pharmaceutical Sciences - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-09-26 |
| Est. Completion | 2025-12-31 |
| Phase | Early Phase 1 |
What NCT06693960 shows while recruiting
NCT06693960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 23-participant average among 3 other Interaction trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Interaction appearing as the primary indexed condition, and to 2 interventions - of which Oregano is the first listed.
NCT06693960 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06693960 about?
NCT06693960 is a clinical study titled "Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach". The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.
What is the current status of trial NCT06693960?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2024-09-26. Estimated completion is 2025-12-31.
What conditions does trial NCT06693960 study?
This clinical trial studies the following conditions: Interaction.
What interventions are being tested in trial NCT06693960?
The interventions under investigation include: Oregano (DIETARY_SUPPLEMENT), Drug cocktail (DRUG).
Who is sponsoring clinical trial NCT06693960?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693960 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI